Prevalence and Pathogenesis of Lung Disease in a Large HIV Cohort-coordinating Center



Status:Active, not recruiting
Conditions:Chronic Obstructive Pulmonary Disease, Pneumonia, HIV / AIDS, Pulmonary
Therapuetic Areas:Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:4/21/2016
Start Date:January 2009
End Date:June 2016

Use our guide to learn which trials are right for you!

Despite the availability of highly active antiretroviral therapy (HAART), lung diseases
remain a leading cause of morbidity and mortality in those with HIV infection. There have
been no large-scale studies detailing pulmonary complications in the HAART era. Substantial
gaps exist in our knowledge of the spectrum and pathogenesis of pulmonary disorders in this
population, particularly in women and minorities whose numbers with HIV or AIDS have
increased. The Multicenter AIDS Cohort Study (MACS) and the Women's Interagency Health Study
(WIHS) are prospective, multi-center cohorts that follow approximately 5000 HIV+ subjects
and HIV- controls. Although pulmonary disease has not been an area of focus, these
established cohorts provide a unique opportunity to systematically study pulmonary
complications of HIV infection.

Emphysema is of particular interest in the current HIV era because it is likely to increase
as this population lives longer with chronic HIV. HIV-infected persons have an increased
incidence of emphysema compared to those without HIV infection, and it has been hypothesized
that this accelerated disease progression is the result of one or more latent infectious
agents that amplify the pulmonary inflammation. Accelerated emphysema was described in HIV
infection in a predominantly male population before HAART. The current prevalence and
characteristics of HIV-associated emphysema, and the potential impact of gender, have not
been rigorously defined.

HIV-infected patients have an increased incidence of emphysema compared to non-HIV-infected
patients, and it has been hypothesized that this accelerated disease progression is the
result of one or more latent infections that amplifies the pulmonary inflammatory response.
We will examine the prevalence and progression of emphysema in subjects with and without HIV
and determine risk factors for emphysema in this population.

Subjects will be 300 HIV+ subjects and 300 HIV- controls selected by random sampling
stratified by age and smoking history. Subjects will be recruited from the University of
Pittsburgh and the University of California Los Angles (UCLA) MACS sites. The University of
California San Francisco (UCSF) will serve as the recruiting center for the WIHS cohort.
Because we are interested in an unbiased estimate of the extent of this disease in HIV
infection, we will not select subjects based on lung function or current diagnosis of COPD.
The HIV- subjects will be matched to the HIV+ subjects in terms of age and smoking history
to the extent possible. Those with symptoms of acute respiratory disease such as fevers,
acute change in cough or shortness of breath, or weight loss will be excluded. There will be
no exclusions based on HAART use or opportunistic infection (OI) prophylaxis and no
exclusions based on previous lung disease as we are trying to obtain a comprehensive
evaluation of emphysema in this population as well as identify associated risk factors.

All subjects will undergo spirometry, diffusing capacity and quantitative CT scanning. These
measurements will allow us to determine differences in the prevalence of emphysema in HIV+
and HIV- and determine risk factors associated with emphysema. For longitudinal studies
testing the hypothesis that emphysema is accelerated in HIV infection, we will select HIV+
and HIV- subjects with documented emphysema in each group as defined by diffusing
capacity<80% predicted, post-bronchodilator FEV1/FVC<70% without significant reversibility,
or at least 10% of lung with a density less than -910 Hounsfield units (HU). These subjects
will have CT scans and PFTs at baseline and at 18 months and 36 months after baseline. At
each visit, clinical data and biological samples will be collected.

Inclusion Criteria:

- Subject is Male / Female 18years of age or older.

- Subject has been previously determined to be HIV-infected or is participating in the
The Multicenter AIDS Cohort Study (MACS) or the Women's Interagency Health Study
(WIHS)

Exclusion Criteria:

- Subject is experiencing acute onset of shortness of breath, cough, fevers or heart
conditions problems such as tachycardia, angina or arrhythmias.

- Female subject has told us she is pregnant (this might affect pulmonary function
values,we will not require pregnancy testing.)

- Subject has had an MI, CVA, or cardiovascular event within the past 3 months.

- Subject has had eye or abdominal surgery within past 3 months.

- Active TB by documentation or self reported will be exclusion criteria to the study.

- Subjects will be excluded from the study if they are unable to sign consent, weigh >
300 pounds due to technical difficulties with the CT/EBCT scanner, or have been
exposed to approximately 10 rads in the previous 12 months (i.e., 2 diagnostic CT
scans or 4 cardiac caths or other fluoroscopic exams).
We found this trial at
2
sites
1635 Divisadero Street
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Los Angeles, California 90095
(310) 825-4321
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials